Navigation Links
Is Aricept, the Alzheimer’s Drug Safe to Use against Vascular Dementia

Eisai is the company which markets Aricept with Pfizer Inc. Aricept is already approved in most markets to treat mild to moderate Alzheimer's disease //, but at present it was being tested in patients with vascular dementia, the second most common form of dementia after Alzheimer's disease.

But the shocking results show that about eleven patients have died while taking Aricept during a clinical trial held at Japan's Eisai Co.

There were no deaths among patients who were taking a placebo. This news would lead to calls for greater scrutiny of clinical trials.

David Windley, an analyst at Jefferies quoted that the deaths were among 648 patients who received Aricept once daily for 24 weeks. There were no deaths in the 326 patients receiving placebos.

The Eisai trial is a Phase 3 study, the final period of testing before companies present proposals to regulators for approval. Sam Gandy, chairman of medical and scientific advisory council of the Alzheimer's Association, said that it was a rather surprising result but the findings cannot negate 10 years of the drug's safety record on the market.

Gandy, who is also director of the neuroscience institute at Thomas Jefferson University in Philadelphia, said that patients taking Aricept in the latest trial showed a statistically significant improvement in cognitive function, compared with those taking placebos.

On the other hand the drug is approved for vascular dementia in a number of smaller markets, including South Korea and India.


'"/>




Page: 1

Related medicine news :

1. Miracle cure for Alzheimer’s around the corner
2. Vaccine for Alzheimer’s diseas
3. High Cholesterol linked to Alzheimer’s diseas
4. Further support for use of statins in Alzheimer’s disease
5. Catching Alzheimer’s Disease Earl
6. Alzheimer’s Continues to Ris
7. Midlife Brain Activity a Predictor Of Alzheimer’s Diseas
8. New Drug Combination Found To Improve Memory in Alzheimer’s Patient
9. Blood Pressure An Early Warning Sign Of Alzheimer’s Disease
10. Delaying The Progression Of Alzheimer’s Disease
11. Hope For Patient With Alzheimer’s Diseas
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:1/23/2017)... ... January 23, 2017 , ... The Masters of Science ... evaluation leaders with decades of experience who remain current practitioners in the field. ... system, there is a renewed demand for versatile, data-driven leadership.The American University’s MS ...
(Date:1/23/2017)... ... January 23, 2017 , ... Moisture measurement is a ... method is paramount to success. Selecting an inappropriate measurement method can cause costly ... use the same equipment. Rare or expensive substances are wasted and production may ...
(Date:1/23/2017)... ... January 23, 2017 , ... Gynecology Associates of ... gynecological services for women of all ages. The staff of Gynecology ... of reproductive services from routine health screenings to diagnosing and treating female concerns ...
(Date:1/23/2017)... ... ... “Some Infallible Characteristics of Christ”: a fascinating and entrancing novel exploring the ... of published author, Rev. Dr. Robert W. Thomas, the third of seven siblings. He ... nineteen, a pastor for over fifteen years. He is a graduate of N.C. College ...
(Date:1/22/2017)... ... January 22, 2017 , ... Medical lab testing through hospitals and ... a simple test will take days to arrive to the end customer, having to ... access to their lab tests, bypassing the cost and delay of traditional means. Now ...
Breaking Medicine News(10 mins):
(Date:1/23/2017)... Jan 23, 2017 Research and Markets has announced ... Trends - Product - Forecast to 2025" report to their offering. ... Report Highlights: ... market trends to identify the investment opportunities Market forecasts ... Key market trends across the business segments, Regions and Countries ...
(Date:1/23/2017)... Jan. 23, 2017  Using Astute Medical,s ... risk for acute kidney injury (AKI) after open-heart ... care guidelines significantly improved outcomes by ... more than 33 percent, according to a ... Intensive Care Medicine. Experience ...
(Date:1/23/2017)... January 23, 2017 Ahead of today,s trading ... how they have fared at the close: Kite Pharma Inc. (NASDAQ: ... OVAS ), and Regeneron Pharmaceuticals Inc. (NASDAQ: ... were relative laggards on Friday, January 20 th , 2017, down ... research reports on these stocks now at: ...
Breaking Medicine Technology: